With Setara, the team behind Actio opens its second act
With Setara, the team behind Actio opens its second act
Setara Biosciences
Private
Clinical-stage biotechnology company developing precision small-molecule ion channel inhibitors for rare genetic and urological disorders, spun out from Actio Biosciences following its acquisition by Jazz Pharmaceuticals.
Company Info
Sector:Small Molecule
Headquarters:San Diego, CA, USA
Founded:2026
Website:setarabiosciences.com/
Funding Round:Series A (October 2026)
Total Funding:$90M Series A
Funding & Investor Relations
Notable Investors
- Canaan Partners
- Deerfield Management
- Droia Ventures
- EcoR1 Capital
Clinical Development Pipeline
STAR-0871
Target: TRPV4STAR-0871
Target: TRPV4Recent News
Leadership Team
David Goldstein
Co-founder & Chief Executive Officer